ACTL, Romidepsin, ICLC, Clinical Trials, T-Cell Lymphoma

Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma

This study is currently recruiting participants.

This study evaluates the safety and tolerability of the addition of immunostimulatory therapy consisting of focal radiation with or without the Toll-like receptor (TLR) agonist Poly ICLC in patients with cutaneous T-cell lymphoma (CTCL) receiving concurrent therapy with the histone deacetylase inhibitor (HDACI) Romidepsin.

Study Type:  Interventional

Study Design:

Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Official Title:  A Pilot Study of a Novel Multimodality Immuno-Chemotherapy Platform for Patients With Advanced Cutaneous T Cell Lymphoma

Condition:  Cutaneous T-cell Lymphoma


Drug: Romidepsin
Drug: Poly ICLC
Radiation: Focal lesional radiation

Phase:  Phase 1

External Link: